The FDA granted a new indication for rucaparib (Rubraca, Clovis Oncology) for the maintenance treatment of recurrent ovarian, fallopian tube and primary peritoneal cancers.
The agency also approved the complementary diagnostic test, FoundationFocus CDx BRCA loss of heterozygosity (LOH), for tumor samples to determine homologous recombination deficiency (HRD) status.
The FDA approved rucaparib, a poly(ADP-ribose) polymerase inhibitor, for the maintenance treatment of recurrent epithelial ovarian,